European Biotech Acquisition’s $200 Million Combination With Oculis

Davis Polk advised European Biotech Acquisition Corp. on the deal while Cooley and Vischer represented Oculis. European Biotech Acquisition Corp. (EBAC), a SPAC, signed its $200 million…

This content is for Standard 1 Year members only.
Login Join Now
Laura Testa

Author: Laura Testa

This content is for Standard 1 Year members only.
Login Join Now